• 1
    Turner WJ. The usefulness of diphenylhydantoin in treatment of non-epileptic emotional disorders [Abstract]. Int J Neuropsychiatry 1967;3(suppl):20.
  • 2
    Okuma T, Kishimoto A, Inoue K, et al. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis: a preliminary report. Folia Psychiatr Neurol Jpn 1973;27: 28397.
  • 3
    Lambert PA, Venaud G. Utilisation de valpromide en therapeutique psychiatrique. L'encephale 1966;8: 36773.
  • 4
    Weisler RH, Kalali AH, Ketter TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004;65: 47884.
  • 5
    Brown D, Silverstone T, Cookson J. Carbamazepine compared to haloperidol in acute mania. Int Clin Psychopharmacol 1989;4: 22938.
  • 6
    Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses: a controlled study. Arch Gen Psychiatry 1984;41: 16570.
  • 7
    Stoll KD, Bisson HE, Fischer E, et al. Carbamazepine versus haloperidol in manic syndromes. In: ShagassC, JosiassenRC, BridgerWH, et al., eds. Biological psychiatry. New York : Elsevier, 1985: 1986: 3324.
  • 8
    Okuma T, Inanaga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology (Berl) 1979;66: 2117.DOI: 10.1007/BF00428308
  • 9
    Small JG, Klapper MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991;48: 91521.
  • 10
    Strömgren LS, Boller S. Carbamazepine in treatment and prophylaxis of manic-depressive disorder. Psychiatr Dev 1985;3: 34967.
  • 11
    Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berl) 2000;150: 1523.DOI: 10.1007/s002130000380
  • 12
    Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: a randomised study. J Affect Disord 1997;43: 15161.DOI: 10.1016/S0165-0327(96)01427-9
  • 13
    Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999;14: 27781.
  • 14
    Greil W, Kleindienst N, Erazo N, et al. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998;18: 45560.DOI: 10.1097/00004714-199812000-00007
  • 15
    Hartong EG, Moleman P, Hoogduin CA, et al. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003;64: 14451.
  • 16
    Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997;58: 4708.
  • 17
    Grunze H, Walden J. Valproat bei manisch-depressiven (bipolaren) Erkrankungen. Stuttgart : Thieme Verlag, 2000.
  • 18
    Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: treatment of mania. World J Biol Psychiatry 2003;4: 513.
  • 19
    Bowden C. The effectiveness of divalproate in all forms of mania and the broader bipolar spectrum: many questions, few answers. J Affect Disord 2004;79(suppl 1):S914.
  • 20
    Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania: the Depakote Mania Study Group. JAMA 1994;271: 918-24.
  • 21
    Swann AC, Bowden CL, Calabrese J, et al. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 2002;26: 5306.DOI: 10.1016/S0893-133X(01)00390-6
  • 22
    Müller-Oerlinghausen B, Retzow A, Henn F, et al. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double- blind, placebo-controlled multicenter study. J Clin Psychopharmacol 2000;20: 195203.DOI: 10.1097/00004714-200004000-00012
  • 23
    McElroy SL, Keck PE, Stanton SP, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996;57: 1426.
  • 24
    Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159: 10117.DOI: 10.1176/appi.ajp.159.6.1011
  • 25
    Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63: 114855.
  • 26
    Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57: 4819.
  • 27
    Hirschfeld R, Weisler RH, Keck PE. Cost-effectiveness evaluation of divalproex versus lithium in the treatment of bipolar disorder: 152nd APA Annual meeting abstracts, NR 686, 1999.
  • 28
    Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160: 126371.DOI: 10.1176/appi.ajp.160.7.1263
  • 29
    Calabrese JR, Woyshville MJ, Kimmel SE, et al. Predictors of valproate response in bipolar rapid cycling. J Clin Psychiatry 1993;13: 2803.
  • 30
    Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance study of lithium versus divalproex monotherapy in bipolar I and II disorder accompanied by rapid cycling [Abstract]. Eur Neuropsychopharmacol 2003;23(suppl.4):227.
  • 31
    Mishory A, Yaroslavsky Y, Bersudsky Y, et al. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 2000;157: 4635.DOI: 10.1176/appi.ajp.157.3.463
  • 32
    Belmaker RH. Propylactic efficacy of phenytoin in bipolar disorder: data presented at the 3rd Conference of Antiepileptic drugs in Psychiatry, Elmau , 2003.
  • 33
    Hellewell JS. Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J Affect Disord 2002;72(suppl 1):2334.DOI: 10.1016/S0165-0327(02)00338-5
  • 34
    Hummel B, Walden J, Stampfer R, et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord 2002;4: 4127.DOI: 10.1034/j.1399-5618.2002.02228.x
  • 35
    Smith D, Chadwick D, Baker G, et al. Seizure severity and quality of life. Epilepsia 1993;34(suppl 5):S315.
  • 36
    Calabrese JR, Bowden CL, Sachs GS, et al. for the Lamictal 602-study group: a double blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999;60: 7988.
  • 37
    Bowden CL, Calabrese JR, Sachs GS, et al. for the Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60: 392400.
  • 38
    Calabrese JR, Bowden CL, Sachs GS, et al., for Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar disorder. J Clin Psychiatry 2003;64: 101324.
  • 39
    Calabrese J, Suppes T, Bowden C, et al., for Lamictal 614 Study Group. A double blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000;61: 84150.
  • 40
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington , DC : American Psychiatric Association , 1994.
  • 41
    Frye M, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20: 60714.DOI: 10.1097/00004714-200012000-00004
  • 42
    Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000;20: 46771.DOI: 10.1097/00004714-200008000-00011
  • 43
    Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19: 3418.DOI: 10.1097/00004714-199908000-00010
  • 44
    Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy: Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000;2: 24955.DOI: 10.1034/j.1399-5618.2000.20305.x
  • 45
    Grunze H, Langosch J, Born C, et al. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry 2003;64: 7814.
  • 46
    McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000;47: 102533.DOI: 10.1016/S0006-3223(99)00316-9
  • 47
    Grunze HC, Normann C, Langosch J, et al. Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J Clin Psychiatry 2001;62: 4648.
  • 48
    Normann C, Langosch J, Schaerer LO, et al. Treatment of acute mania with topiramate [Letter]. Am J Psychiatry 1999;156: 2014.
  • 49
    Grunze H, Erfurth A, Marcuse A, et al. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999;60: 75962.
  • 50
    Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry 2004;65(suppl 10):2835.
  • 51
    Suppes T, Chisholm KA, Dhavale D, et al. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord 2002;4: 2839.DOI: 10.1034/j.1399-5618.2002.01201.x
  • 52
    Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999;156: 101923.